REGENERON PHARMACEUTICALS, INC. 8-K

What Happened

• Regeneron Pharmaceuticals, Inc. (Regeneron) filed an 8-K reporting the results of its Annual Meeting of Shareholders held June 12, 2026. All nominated Class II directors were elected to serve until the 2027 Annual Meeting. The company also reported shareholder votes to ratify PricewaterhouseCoopers LLP (PwC) as its independent auditor and an advisory (non-binding) vote to approve executive compensation.

Key Details

• Director elections (terms until 2027):
  • Joseph L. Goldstein, M.D.: For 72,398,297; Against 30,904,254; Abstain 170,603; Broker non-votes 5,543,411.
  • Christine A. Poon: For 79,409,070; Against 24,004,880; Abstain 59,204; Broker non-votes 5,543,411.
  • David P. Schenkein, M.D.: For 99,241,219; Against 4,180,107; Abstain 51,828; Broker non-votes 5,543,411.
  • Craig B. Thompson, M.D.: For 81,933,651; Against 21,378,567; Abstain 160,936; Broker non-votes 5,543,411.
  • Huda Y. Zoghbi, M.D.: For 100,665,234; Against 2,698,397; Abstain 109,523; Broker non-votes 5,543,411.
• Auditor ratification: PwC was ratified as Regeneron’s independent registered public accounting firm for fiscal 2026 — For 102,503,788; Against 6,443,958; Abstain 68,819.
• Advisory vote on executive compensation: Approved (non-binding) — For 96,469,374; Against 6,898,268; Abstain 105,512; Broker non-votes 5,543,411.

Why It Matters

• These outcomes confirm the board composition and auditor for the coming year, which affect corporate oversight and financial reporting. The advisory approval of executive pay signals shareholder support for the company’s disclosed compensation practices, though it is non-binding. Investors can use the vote tallies (including sizeable against votes on some director nominees) as one measure of shareholder sentiment toward governance and leadership.